Drug pricing is the most misunderstood subject in healthcare, and the confusion is not accidental: the system is genuinely opaque, and almost nobody pays the price you see in the headline. The list price of a drug and the money the manufacturer actually keeps can differ enormously, because of a chain of rebates and discounts flowing through intermediaries most people have never heard of. Here is a clear explanation of how it actually works.
List price is not the real price
Start with the crucial distinction. The list price (often called the wholesale acquisition cost) is the sticker price a manufacturer sets. The net price is what the manufacturer actually retains after all the rebates, discounts, and fees it pays out. The gap between the two, known as the gross-to-net difference, has grown very large for many drugs, particularly in competitive categories. This is why a drug’s list price can rise while the manufacturer’s actual revenue per prescription falls, a dynamic that genuinely confuses public debate and makes headline prices a poor guide to what anyone is really paying or earning.
The players in the chain
- Manufacturers set the list price and pay rebates to secure access.
- Wholesalers distribute drugs and take a margin.
- Pharmacy benefit managers negotiate on behalf of insurers, deciding which drugs are on the formulary and at what tier, and extracting rebates from manufacturers in exchange for favorable placement. They are the most consequential and least understood actor in the system.
- Insurers and payers decide what they will cover and what patients pay.
- Pharmacies dispense and are reimbursed.
- Patients pay a copay or coinsurance, which, crucially, is sometimes calculated from the list price rather than the discounted net price, which is why patients can pay more than the insurer effectively did.
Why rebates distort everything
The rebate system creates a genuinely perverse dynamic. To win favorable formulary placement, manufacturers offer larger rebates, and because rebates are often calculated as a percentage of list price, a higher list price allows a bigger rebate while leaving the net price unchanged. This creates pressure to raise list prices even when the manufacturer captures none of the increase. Meanwhile patients whose costs are tied to list price pay more, and public outrage focuses on list prices that no longer reflect economic reality. Nearly every serious pricing reform proposal targets some part of this dynamic, and it explains much of why the system looks irrational from the outside.
How prices actually get set
Manufacturers set prices based on several factors. Clinical value, how much better the drug is than existing options, is the foundation of the argument. Competition matters enormously, since a drug with alternatives has far less pricing power than one that is genuinely unique. The value narrative for payers matters, including whether the drug offsets other costs like hospitalizations. The size of the treated population shapes strategy: rare disease drugs command extraordinary per-patient prices precisely because so few patients need them, while common-disease drugs price lower and rely on volume. And anticipated rebates are baked in from the start, since the list price is set knowing much of it will be given back.
What is changing
The system is under real pressure. Medicare now negotiates prices directly for selected high-spending drugs, with the first negotiated prices having taken effect in 2026, and the program expands each year. Caps on patient out-of-pocket spending have made a tangible difference for people with high drug costs. There is ongoing scrutiny of the rebate system and the role of pharmacy benefit managers, and proposals to tie US prices to those paid in other countries continue to surface. For drug developers, the practical implication is that pricing can no longer be treated as a late-stage commercial question; it is a strategic consideration that shapes development decisions from early on.
The bottom line
Drug pricing looks irrational because the visible number, the list price, has been progressively detached from the economics by a rebate system that rewards high list prices and channels value through intermediaries. Understanding the difference between list and net, the role of pharmacy benefit managers, and the perverse incentives of rebates explains most of what seems inexplicable about the system. For anyone in the industry, the key takeaway is that the pricing environment is tightening, the scrutiny is intensifying, and the companies that plan for this reality early, rather than treating price as something to determine at launch, will navigate it best.
What this means for a biotech setting a price
For a company approaching its first launch, the practical implications of this system are considerable and often underappreciated. The first is that pricing strategy must begin years before launch, not at the end, because the evidence payers will demand to justify your price has to be generated during your clinical program. If you have not collected the health economic and outcomes data that demonstrate your drug’s value, you cannot make the value argument, and it is far too late to start once the trial is complete. This is why payer and market access input belongs in trial design conversations, a point many first-time companies learn painfully. The second is that the list price you set is not the revenue you receive, and building a financial model that ignores the rebates you will need to pay for formulary access produces forecasts that are simply wrong. Understanding the likely gross-to-net gap in your category is essential to any credible revenue projection. The third is that access matters as much as approval: a drug that is approved but poorly positioned on formularies, or burdened with prior authorization requirements that discourage prescribing, will underperform regardless of its clinical merit, so the commercial work of securing access is as consequential as the regulatory work of securing approval. And the fourth is that the environment is tightening, so a pricing strategy that assumed the freedom of a decade ago is likely to disappoint. Companies that engage market access expertise early, generate the evidence payers want, and model the real economics rather than the list price give themselves a far better chance of translating a good drug into a commercially successful one.
The bottom line, restated
Drug pricing appears irrational because the visible number has been progressively detached from the economics by a rebate system that rewards high list prices and routes value through intermediaries. Understanding list versus net, the role of pharmacy benefit managers, and the perverse incentives baked into rebates explains most of what looks inexplicable. For companies, the practical lesson is that pricing and access strategy must start years before launch, that the evidence payers demand has to be generated during development, and that a revenue model built on list price is a model built on a number nobody actually pays.
Start the access conversation early
The practical action that most improves a launch is to bring market access thinking into development years ahead of approval. Ask, while the trial is still being designed, what evidence payers will require to reimburse this drug, and make sure you collect it. Ask who will actually pay, what they will compare you against, and what value argument will persuade them. Companies that answer these questions during development launch into a market prepared to pay for their drug; companies that ask them after approval spend years catching up, and some never do.
For expert help with pricing, market access, and regulatory strategy, browse the BioMed Nexus regulatory and compliance directory, and see our related piece on the IRA and what it means for biotech.
Frequently asked questions
What is the difference between list price and net price?
The list price (wholesale acquisition cost) is the sticker price a manufacturer sets. The net price is what the manufacturer actually keeps after paying rebates, discounts and fees. The gap, called gross-to-net, has grown very large for many drugs, which is why a drug's list price can rise while the manufacturer's actual revenue per prescription falls.
Why do drug list prices keep rising?
Partly because of how rebates work. To win favorable formulary placement, manufacturers offer rebates to pharmacy benefit managers, and because rebates are often a percentage of list price, a higher list price allows a bigger rebate while leaving the net price unchanged. This creates pressure to raise list prices even when the manufacturer captures none of the increase.
What does a pharmacy benefit manager do?
A pharmacy benefit manager negotiates on behalf of insurers, deciding which drugs appear on the formulary and at what tier, and extracting rebates from manufacturers in exchange for favorable placement. They are among the most consequential and least understood actors in US drug pricing, and they are a frequent target of reform proposals.
